These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9158969)

  • 1. Haggling for a patent: what a government would have to pay for prescription drug patents.
    Guell RC
    Health Econ; 1997; 6(2):179-85. PubMed ID: 9158969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward allocative efficiency in the prescription drug industry.
    Guell RC; Fischbaum M
    Milbank Q; 1995; 73(2):213-30. PubMed ID: 7776946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug patent protection: how long is long enough?
    Sibbald B
    CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
    [No Abstract]   [Full Text] [Related]  

  • 5. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Affordable Prescription Drugs Act: a solution for today's high prescription drug prices.
    Pinzone JD
    J Law Health; 2001-2002; 16(1):145-68. PubMed ID: 14650775
    [No Abstract]   [Full Text] [Related]  

  • 7. Lowering the cost of prescription drugs.
    Jindal B
    J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276
    [No Abstract]   [Full Text] [Related]  

  • 8. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
    Openshaw MS
    Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Government Patent Use': A Legal Approach To Reducing Drug Spending.
    Kapczynski A; Kesselheim AS
    Health Aff (Millwood); 2016 May; 35(5):791-7. PubMed ID: 27140984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An ethical dilemma. Patents & profits v. access & affordability.
    Blasi AE
    J Leg Med; 2012 Jan; 33(1):115-28. PubMed ID: 22439710
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug firms lose patent rights lawsuit against South Africa's government.
    Baleta A
    Lancet; 2001 Apr; 357(9265):1347. PubMed ID: 11343755
    [No Abstract]   [Full Text] [Related]  

  • 12. A free market solution for prescription drug crises.
    Baker D
    Int J Health Serv; 2004; 34(3):517-26. PubMed ID: 15346683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The other drug lords.
    Novak V
    Int J Health Serv; 1993; 23(2):263-73. PubMed ID: 8500946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are prescription drug prices high?
    Vagelos PR
    Science; 1991 May; 252(5009):1080-4. PubMed ID: 2031182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic justification for open access to essential medicine patents in developing countries.
    Flynn S; Hollis A; Palmedo M
    J Law Med Ethics; 2009; 37(2):184-208. PubMed ID: 19493066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pricing and welfare implications of parallel imports in the pharmaceutical industry.
    Jelovac I; Bordoy C
    Int J Health Care Finance Econ; 2005 Mar; 5(1):5-21. PubMed ID: 15714261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patents, pills and politics: the Australia-United States Free Trade Agreement and the Pharmaceutical Benefits Scheme.
    Harvey K
    Aust Health Rev; 2004 Nov; 28(2):218-26. PubMed ID: 15527402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The consumer welfare implications of governmental policies and firm strategy in markets for medicines.
    Chatterjee C; Kubo K; Pingali V
    J Health Econ; 2015 Dec; 44():255-73. PubMed ID: 26581076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How drug life-cycle management patent strategies may impact formulary management.
    Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
    Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.